Zealand Pharma has invented a glucagon analogue, ZP-GA-1, with increased stability in liquid formulation for treatment of hypoglycemia. A pharmacodynamic (PD) model is needed to compare ZP-GA-1 with marketed glucagon. We aim to develop a model of the complex glucose-insulin-glucagon dynamics based on physiology and data.
|Number of pages||1|
|Publication status||Published - 2016|
|Event||9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016) - Milan, Italy|
Duration: 3 Feb 2016 → 6 Feb 2016
Conference number: 9
|Conference||9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016)|
|Period||03/02/2016 → 06/02/2016|